In this article, we will look at the 11 Best Pharma Stocks to Buy According to Hedge Funds.
Why is China the Talk of the Town in the Pharma Industry?
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China. According to data from DealForma, as reported by CNBC, around 30% of Big Pharma deals with at least $50 million upfront in 2024 included Chinese companies. This was up from 20% the year before and almost 0% only five years prior.
Experts are attributing several reasons to this trend. Some believe that Chinese pharmaceutical companies are attracting attention because of their advanced development capabilities that are producing effective molecules in substantial quantities. These Chinese companies are also in a position to assign a lower price to these medicines compared to the US, and are capable of initiating their testing on human subjects quicker. According to CNBC, buyers have devised a business model allowing them to import medicines through licensing deals. Biotech companies are further pushed into making these deals due to the drying up of venture funding in China.
Although the potential reasons for this trend vary, experts believe this scenario is here to stay. While it is anticipated to affect the US pharmaceutical sector, how these repercussions might materialize is unclear. Some experts believe it could ruin American startups if large pharmaceutical companies stumble upon a promising Chinese drug at a low price; others believe the competition would be fruitful for the industry. CNBC reported that Tim Opler, a managing director in Stifel’s global healthcare group, said the following about the situation:
“It’s kind of a watershed moment where the pharma industry is like, ‘We don’t really need to buy U.S. biotechs necessarily. We will if it makes sense, but we can buy perfectly good biotech assets through licensing deals with Chinese companies.”
How Will the Pharma Industry Perform in 2025?
We talked about the potential performance of the pharma industry in a recently published article on 10 Oversold Pharma Stocks to Buy According to Analysts. Here is an excerpt from the article:
“On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity drugs. She believed the industry may not underperform this year, at least in the first half. However, there are still several questions surrounding the performance of obesity drugs, as major players in the domain have exhibited contrasting previous year performance.
Talking about the tariffs, she said that their materialization poses a big open question for the pharmaceutical sector as some companies assemble their products in the US after manufacturing them abroad. Manufacturing costs are thus pretty low for these companies, which is a significant point to consider when determining the impact of tariffs. She believed that absorbing the additional cost of the tariffs would be very manageable for these companies. The market has reached the tail-end of the earnings season, and the situation hasn’t come up much on earnings calls over this quarter.”
With these trends in view, let’s look at the 11 best pharma stocks to buy according to hedge funds.
A closeup view of a magnified pharmaceutical tablet.
Our Methodology
We sifted through stock screeners, online rankings, and ETFs to compile a list of 25 pharma stocks. We then selected the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Pharma Stocks to Buy According to Hedge Funds
11. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Number of Hedge Fund Holders: 68
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions. The company is advancing around 40 of its programs. It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea. Dupixent is an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) comarkets with Bayer, treats wet age-related macular generation.
While the company’s products are under pressure due to competition for its Eylea franchise, analysts believe Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) stock could grow by 50% from its current levels in the next year. This optimism is because, despite pressures, the company grew its total revenue by 10% year-over-year to $3.8 billion in fiscal Q4 2024. The positive performance was primarily due to Dupixent, which recorded a 15% year-over-year growth in its worldwide net sales to $3.7 billion in fiscal Q4 2024.
Dupixent ranked among the 10 best-selling drugs in the world last year. To continue this momentum, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi are seeking a label expansion for the drug to treat a rare skin disease called bullous pemphigoid. If approved, Dupixent would become the first targeted drug in this narrow indication in the US.
10. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Number of Hedge Fund Holders: 68
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops medicines for rare serious diseases. Its four approved medicines treat cystic fibrosis (CF), and one approved therapy treats severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company’s product pipeline includes clinical-stage programs for various disorders, including TDT, SCD, CF, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency.
Despite struggles in the healthcare sector, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has outperformed the broader market and its biotech peers since 2022. It holds a dominant position in the cystic fibrosis market and is expanding its offerings beyond it. The company recently attained approval for Alyftrek to treat CF, further consolidating its presence in the market. It has low market competition and patents locked up into the 2030s, which is why investors are bullish on the stock.
Another reason behind this bullish sentiment is the recent regulatory approval Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) attained for Journavx (formerly known as suzetrigine) to treat acute pain. The drug does not have the addiction risks associated with opioid painkillers and delivers excellent pain relief, ranking this oral non-opioid pain signal inhibitor among the first new class of pain medicine in over 20 years.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) also has strong fundamentals. It delivered $2.91 billion in revenue in fiscal Q4 2024, representing 16% growth versus Q4 2023. For the full year 2024, revenue reached a record of just over $11 billion, reflecting a 12% growth versus 2023 and exceeding the company’s full-year product revenue guidance. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks tenth on our list of the 11 best pharma stocks to buy according to hedge funds.